Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBI-1501 in healthy adults
NCT02826798Phase 1Completed
- Sponsor
- VBI Vaccines Inc.
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VBI-1501 in cytomegalovirus infection (CMV) (5 arms), sponsored by VBI Vaccines Inc. Primary endpoints: Number of Participants With Local and Systemic Adverse Events, Number of Participants With Any Adverse Event and 2 more. Started Jun 2016; status: completed.
02
Drugs
VBI-1501
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02826798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826798.